ASTELLAS PHARMA INC./ JP3942400007 /
07/11/2024 19:39:08 | Var. -0.040 | Volume | Denaro21:55:02 | Lettera21:55:02 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
---|---|---|---|---|---|---|---|
10.400EUR | -0.38% | 3,451 Fatturato: 36,081.035 |
10.145Quantità in denaro: 481 | 10.460Quantità in lettera: 472 | 18.94 bill.EUR | - | - |
GlobeNewswire
14/08
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08/08
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
GlobeNewswire
16/04
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
19/03
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degene...
GlobeNewswire
26/02
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
07/02
LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veter...
GlobeNewswire
11/12/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
19/10/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
14/09/2023
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
11/09/2023
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors